Biography
Biography: Salah Aref
Abstract
Chronic lymphocytic leukemia (CLL) is clonal B cell neoplasm, most frequent in the old age. The clinical course is very heterogenous with the survival time ranging from months to decade. Recently, it was appeared that underlying this heterogeneity are genetic mutation disease progress. In recent years, the development of target therapy necessitates the determination of these generic mutations to tailor the therapy for each patient. In this presentation, we give spotlight on the genetic mutations in CLL and its role in affecting the patient course and treatment.